 Connection
Michael Bristow to Adrenergic beta-Agonists
This is a "connection" page, showing publications Michael Bristow has written about Adrenergic beta-Agonists.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.821 |
|
|
|
-
Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec; 81(2-3):141-9.
Score: 0.179
-
Lindenfeld J, Lowes BD, Bristow MR. Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol. Ann Pharmacother. 1999 Dec; 33(12):1266-9.
Score: 0.156
-
Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, Bristow MR. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995 Dec; 108(6):1524-32.
Score: 0.118
-
Port JD, Gilbert EM, Larrabee P, Mealey P, Volkman K, Ginsburg R, Hershberger RE, Murray J, Bristow MR. Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. Circulation. 1990 Mar; 81(3):929-38.
Score: 0.079
-
Bristow MR, Port JD, Hershberger RE, Gilbert EM, Feldman AM. The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure. Eur Heart J. 1989 Jun; 10 Suppl B:45-54.
Score: 0.075
-
Sucharov CC, Mariner PD, Nunley KR, Long C, Leinwand L, Bristow MR. A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am J Physiol Heart Circ Physiol. 2006 Sep; 291(3):H1299-308.
Score: 0.060
-
Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002 Oct 02; 40(7):1248-58.
Score: 0.047
-
Port JD, Bristow MR. beta-Adrenergic receptors, transgenic mice, and pharmacological model systems. Mol Pharmacol. 2001 Oct; 60(4):629-31.
Score: 0.044
-
Bristow MR, Hershberger RE, Port JD, Minobe W, Rasmussen R. Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol. 1989 Mar; 35(3):295-303.
Score: 0.019
-
Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986 Sep; 59(3):297-309.
Score: 0.016
-
Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 1985 Jul; 17 Suppl 2:41-52.
Score: 0.014
-
Ginsburg R, Esserman LJ, Bristow MR. Myocardial performance and extracellular ionized calcium in a severely failing human heart. Ann Intern Med. 1983 May; 98(5 Pt 1):603-6.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|